Compare Appian Corp (APPN) vs ClearPoint Neuro Inc (CLPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Appian Corp vs ClearPoint Neuro Inc — how do they compare? Appian Corp trades at $35.5 (market cap $2.55B), while ClearPoint Neuro Inc trades at $14.92 (market cap $444.14M). The key difference: Appian Corp is far larger — about 5.7× ClearPoint Neuro Inc's market cap, and Appian Corp is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| APPN | CLPT | |
|---|---|---|
Market Cap | $2.55B | $444.14M |
Sector | Technology | Health |
52-Week High | $45.64 | $29.60 |
52-Week Low | $18.72 | $8.66 |
Enterprise Value | $2.68B | $478.72M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Appian (APPN) surged 13.91% to $34.64 following strong Q2 2026 earnings that exceeded expectations, with cloud subscription revenue growing 23% year-over-year. The stock trades near its pivot point of $34 with bullish technical signals from moving averages, though RSI levels suggest potential overbought conditions. Revenue growth has accelerated from $617M in 2024 to $727M in 2025, with the company achieving its first profitable year with $1.23M net income after several years of losses.
Appian demonstrates improving fundamentals with consistent revenue growth and recent profitability, though negative equity and high debt levels present risks. Analyst sentiment is mixed with 31.58% buy ratings but a consensus price target of $32.50 below current levels. The AI-driven workflow platform shows strong enterprise adoption, but investors should weigh growth potential against valuation concerns and competitive pressures in the low-code automation space.
ClearPoint Neuro (CLPT) trades at $14.21, up 6.12% today, amid mixed technical signals and challenging fundamentals. The company reported Q2 2026 revenue growth but missed earnings expectations with a loss of $0.38 per share, continuing a trend of negative profitability. Despite 100% analyst buy ratings, financial metrics show significant losses with a net income margin of -81.76% and negative cash flow from operations of $30 million projected for 2026.
The investment case hinges on regulatory progress and partnership developments in neurotechnology, but substantial execution risks and persistent losses present headwinds. While analyst consensus remains bullish on long-term potential, current financial performance suggests cautious optimism is warranted until profitability improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →
